Physician profile
Barbara Reed
NPI 1083864268
$8,015.18
in general payments reported to CMS, 2019-2025
26 companies · $2,742 in 2025
The $2,742 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,518 · 2022: $89.25 · 2023: $1,819 · 2024: $1,846 · 2025: $2,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,407 · Education: $1.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,406.87 |
| Education | $1.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,439.25 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,285.93 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,163.32 | 2021-2025 | |
| Axsome Therapeutics, INC. | $965.28 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $634.94 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $348.44 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $291.61 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $252.36 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $251.24 | 2021-2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $238.54 | 2021-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $230.37 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $202.92 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $198.04 | 2021-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $191.84 | 2021-2025 | Fanapt |
| Adlon Therapeutics L.P. | $83.58 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $35.15 | 2021 | |
| Merck Sharp & Dohme LLC | $33.13 | 2021 | |
| Owp Pharmaceuticals, INC. | $29.83 | 2023 | Lamotrigine, Subvenite |
| Amgen INC. | $23.88 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.91 | 2021 | |
| Eisai INC. | $19.50 | 2021 | |
| Noven Therapeutics, LLC | $19.28 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.47 | 2021 | |
| Biogen, INC. | $14.98 | 2025 | Zurzuvae |
| Indivior INC. | $14.60 | 2021 | |
| Almatica Pharma LLC | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.